Reply
Roongruedee Chaiteerakij, William S. Harmsen, Euijung Ryu, Rosebud O. Roberts, Janet E. Olson, Terry M. Therneau, Lewis R. Roberts – 8 April 2013
Reply
Michael R. Lucey, Norah Terrault – 5 April 2013
Now you see it, now you don't
Eileen Plotkin, David N. Assis, James L. Boyer – 4 April 2013
Now you see it, now you don't
Eileen Plotkin, David N. Assis, James L. Boyer – 4 April 2013
Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial
Zobair Younossi, Francesco Negro, Lawrence Serfaty, Stanislas Pol, Moises Diago, Stefan Zeuzem, Pietro Andreone, Eric J. Lawitz, Stuart Roberts, Roberto Focaccia, Graham R. Foster, Andrzej Horban, Isabelle Lonjon‐Domanec, Bruce Coate, Ralph DeMasi, Gaston Picchio, James Witek – 4 April 2013 – Baseline homeostasis model assessment‐estimated insulin resistance (HOMA‐IR), a marker for insulin resistance, has been associated with poor virologic response to peginterferon alpha/ribavirin (PR) in chronic hepatitis C.
Small steps toward a better treatment for chronic hepatitis C infection: mericitabine, pegylated interferon, and ribavirin in the PROPEL and JUMP‐C trials
Dawn M. Torres, Stephen A. Harrison – 4 April 2013
Response‐guided peginterferon therapy in hepatitis B e antigen‐positive chronic hepatitis B using serum hepatitis B surface antigen levels
Milan J. Sonneveld, Bettina E. Hansen, Teerha Piratvisuth, Ji‐Dong Jia, Stefan Zeuzem, Edward Gane, Yun‐Fan Liaw, Qing Xie, E. Jenny Heathcote, Henry L.‐Y. Chan, Harry L.A. Janssen – 2 April 2013 – On‐treatment levels of hepatitis B surface antigen (HBsAg) may predict response to peginterferon (PEG‐IFN) therapy in chronic hepatitis B (CHB), but previously proposed prediction rules have shown limited external validity. We analyzed 803 HBeAg‐positive patients treated with PEG‐IFN in three global studies with available HBsAg measurements.
Pegylated interferon and ribavirin: a therapeutic option in patients who fail to respond to telaprevir‐based triple therapy?
Chia‐Yen Dai, Wan‐Long Chuang, Ming‐Lung Yu – 2 April 2013
Reply:
Edmondo Falleti, Carlo Fabris, Pierluigi Toniutto – 2 April 2013
Imaging mass spectrometry reveals modified forms of histone H4 as new biomarkers of microvascular invasion in hepatocellular carcinomas
Nicolas Poté, Theodore Alexandrov, Julie Le Faouder, Samira Laouirem, Thibaut Léger, Mouniya Mebarki, Jacques Belghiti, Jean‐Michel Camadro, Pierre Bedossa, Valérie Paradis – 2 April 2013 – Microvascular invasion (MiVI) is a major risk factor in postoperative tumor recurrence and mortality in hepatocellular carcinoma (HCC). Unfortunately, this histological feature is usually missed by liver biopsy because of limited sampling, and MiVI is commonly detected only after surgery and examination of the full resected specimen.